128 related articles for article (PubMed ID: 37021589)
1. Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome.
Rozalem Aranha M; Iulita MF; Montal V; Pegueroles J; Bejanin A; Vaqué-Alcázar L; Grothe MJ; Carmona-Iragui M; Videla L; Benejam B; Arranz J; Padilla C; Valldeneu S; Barroeta I; Altuna M; Fernández S; Ribas L; Valle-Tamayo N; Alcolea D; González-Ortiz S; Bargalló N; Zetterberg H; Blennow K; Blesa R; Wisniewski T; Busciglio J; Cuello AC; Lleó A; Fortea J
Alzheimers Dement; 2023 Nov; 19(11):4817-4827. PubMed ID: 37021589
[TBL] [Abstract][Full Text] [Related]
2. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome.
Belbin O; Xiao MF; Xu D; Carmona-Iragui M; Pegueroles J; Benejam B; Videla L; Fernández S; Barroeta I; Nuñez-Llaves R; Montal V; Vilaplana E; Altuna M; Clarimón J; Alcolea D; Blesa R; Lleó A; Worley PF; Fortea J
Mol Neurodegener; 2020 Aug; 15(1):46. PubMed ID: 32807227
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernández S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Alcolea D; Clarimón J; Zaman SH; Blesa R; Lleó A
Lancet; 2020 Jun; 395(10242):1988-1997. PubMed ID: 32593336
[TBL] [Abstract][Full Text] [Related]
5. Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease.
Cantero JL; Atienza M; Lage C; Zaborszky L; Vilaplana E; Lopez-Garcia S; Pozueta A; Rodriguez-Rodriguez E; Blesa R; Alcolea D; Lleo A; Sanchez-Juan P; Fortea J;
Cereb Cortex; 2020 Apr; 30(4):2083-2098. PubMed ID: 31799623
[TBL] [Abstract][Full Text] [Related]
6. Cortical microinfarcts in adults with Down syndrome assessed with 3T-MRI.
Aranha MR; Montal V; van den Brink H; Pegueroles J; Carmona-Iragui M; Videla L; Maure Blesa L; Benejam B; Arranz J; Valldeneu S; Barroeta I; Fernández S; Ribas L; Alcolea D; González-Ortiz S; Bargalló N; Biessels GJ; Blesa R; Lleó A; Coutinho AM; Leite CC; Bejanin A; Fortea J
Alzheimers Dement; 2024 Jun; 20(6):3906-3917. PubMed ID: 38644660
[TBL] [Abstract][Full Text] [Related]
7. AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome.
Hartley SL; Handen B; Tudorascu D; Lee L; Cohen A; Schworer EK; Peven JC; Zammit M; Klunk W; Laymon C; Minhas D; Luo W; Zaman S; Ances B; Preboske G; Christian BT;
Alzheimers Dement; 2024 Jan; 20(1):366-375. PubMed ID: 37641428
[TBL] [Abstract][Full Text] [Related]
8. Cortical Amyloid Burden Relates to Basal Forebrain Volume in Subjective Cognitive Decline.
Daamen M; Scheef L; Li S; Grothe MJ; Gaertner FC; Buchert R; Buerger K; Dobisch L; Drzezga A; Essler M; Ewers M; Fliessbach K; Herrera Melendez AL; Hetzer S; Janowitz D; Kilimann I; Krause BJ; Lange C; Laske C; Munk MH; Peters O; Priller J; Ramirez A; Reimold M; Rominger A; Rostamzadeh A; Roeske S; Roy N; Scheffler K; Schneider A; Spottke A; Spruth EJ; Teipel SJ; Wagner M; Düzel E; Jessen F; Boecker H;
J Alzheimers Dis; 2023; 95(3):1013-1028. PubMed ID: 37638433
[TBL] [Abstract][Full Text] [Related]
9. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study.
Zhang H; Lyu D; Jia J;
J Alzheimers Dis; 2022; 85(4):1441-1452. PubMed ID: 34958042
[TBL] [Abstract][Full Text] [Related]
10. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Basal Forebrain Degeneration Interacts with TREM2/C3 Biomarkers of Inflammation in Presymptomatic Alzheimer's Disease.
Schmitz TW; Soreq H; Poirier J; Spreng RN
J Neurosci; 2020 Feb; 40(9):1931-1942. PubMed ID: 31915256
[TBL] [Abstract][Full Text] [Related]
12. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
13. Antemortem basal forebrain atrophy in pure limbic TAR DNA-binding protein 43 pathology compared with pure Alzheimer pathology.
Teipel SJ; Grothe MJ;
Eur J Neurol; 2022 May; 29(5):1394-1401. PubMed ID: 35122358
[TBL] [Abstract][Full Text] [Related]
14. Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum.
Teipel SJ; Dyrba M; Ballarini T; Brosseron F; Bruno D; Buerger K; Cosma NC; Dechent P; Dobisch L; Düzel E; Ewers M; Fliessbach K; Haynes JD; Janowitz D; Kilimann I; Laske C; Maier F; Metzger CD; Munk MH; Peters O; Pomara N; Preis L; Priller J; Ramírez A; Roy N; Scheffler K; Schneider A; Schott BH; Spottke A; Spruth EJ; Wagner M; Wiltfang J; Jessen F; Heneka MT
J Alzheimers Dis; 2022; 85(3):1267-1282. PubMed ID: 34924387
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
16. Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome.
Bejanin A; Iulita MF; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernandez S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Padilla C; Aranha MR; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Zetterberg H; Blennow K; Alcolea D; Clarimon J; Zaman SH; Blesa R; Lleó A; Fortea J
JAMA Neurol; 2021 Aug; 78(8):937-947. PubMed ID: 34228042
[TBL] [Abstract][Full Text] [Related]
17. Atrophy of the cholinergic Basal forebrain over the adult age range and in early stages of Alzheimer's disease.
Grothe M; Heinsen H; Teipel SJ
Biol Psychiatry; 2012 May; 71(9):805-13. PubMed ID: 21816388
[TBL] [Abstract][Full Text] [Related]
18. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
Rafii MS; Lukic AS; Andrews RD; Brewer J; Rissman RA; Strother SC; Wernick MN; Pennington C; Mobley WC; Ness S; Matthews DC;
J Alzheimers Dis; 2017; 60(2):439-450. PubMed ID: 28946567
[TBL] [Abstract][Full Text] [Related]
19. Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome.
Montal V; Barroeta I; Bejanin A; Pegueroles J; Carmona-Iragui M; Altuna M; Benejam B; Videla L; Fernández S; Padilla C; Aranha MR; Iulita MF; Vidal-Piñeiro D; Alcolea D; Blesa R; Lleó A; Fortea J;
Ann Neurol; 2021 Sep; 90(3):407-416. PubMed ID: 34309066
[TBL] [Abstract][Full Text] [Related]
20. The basal forebrain volume reduction detected by MRI does not necessarily link with the cholinergic neuronal loss in the Alzheimer's disease mouse model.
Zhou XA; Ngiam G; Qian L; Sankorrakul K; Coulson EJ; Chuang KH
Neurobiol Aging; 2022 Sep; 117():24-32. PubMed ID: 35640461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
